Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Stock Information for GlycoMimetics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GlycoMimetics Inc.

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.